FMRI of Cholinergic Mechanisms in Schizophrenia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2012 by VA Eastern Colorado Health Care System.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by (Responsible Party):
VA Eastern Colorado Health Care System
ClinicalTrials.gov Identifier:
NCT00692679
First received: June 3, 2008
Last updated: July 25, 2012
Last verified: July 2012
  Purpose

This study will examine brain responses during sensory processing in patients with schizophrenia. It will examine the hypothesis that patients treated with clozapine will show decreased responses during sensory processing as compared to patients treated with risperidone.


Condition
Schizophrenia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: FMRI of Cholinergic Mechanisms in Schizophrenia

Resource links provided by NLM:


Further study details as provided by VA Eastern Colorado Health Care System:

Primary Outcome Measures:
  • BOLD FMRI response in hippocampus [ Time Frame: Various ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: May 2010
Groups/Cohorts
1
Patients treated with clozapine
2
Patients treated with risperidone.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Patients with schizophrenia

Criteria

Inclusion Criteria:

  • Diagnosis of schizophrenia
  • treatment with clozapine or risperidone

Exclusion Criteria:

  • Metal in body including pacemaker, aneurism clip, weight over 300 lbs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00692679

Locations
United States, Colorado
University of Colorado Denver Medical School Not yet recruiting
Denver, Colorado, United States, 80262
Contact: JASON TREGELLAS, Ph.D.    303-315-1086    Jason.Tregellas@uchsc.edu   
Dept. of Veterans Affairs Medical Center Not yet recruiting
Denver, Colorado, United States, 80220
Contact: JASON TREGELLAS, Ph.D.    303-315-1086    Jason.Tregellas@uchsc.edu   
Sponsors and Collaborators
VA Eastern Colorado Health Care System
  More Information

No publications provided

Responsible Party: VA Eastern Colorado Health Care System
ClinicalTrials.gov Identifier: NCT00692679     History of Changes
Other Study ID Numbers: 07-1261
Study First Received: June 3, 2008
Last Updated: July 25, 2012
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 02, 2014